N/A N=33 Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye
Glaucoma
Primary: Lamina Cribrosa (Boundaries of the Retinal Layers) Measurements — 264.3; 273.3; 276.2 micro-ohms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 SDOCT-GMPE Software
Glaucoma
Primary: Retinal Nerve Fiber Layer (RNFL) Thickness Correlation Width Global Bruch's Membrane Opening-minimum Rim Width (BMO-MRW) — 0.70 correlation coefficient
N/A N=4,812 A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Percentage of Patients With a Reduction in Intraocular Pressure (IOP) ≥ 5mmHg From Baseline — 75.9 Millimeters of Mercury (mmHg)
N/A N=102 Study Comparing Quantitative Assessments in Open-angle Glaucoma (OAG) and/or Ocular Hypertension (OHT)
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Intra- Examiner Agreement in Angle Width by Goniometric Lens — 0.88 Kappa statistics
N/A N=136 How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?
Glaucoma Diagnosis
Primary: Visual Evoked Potential (VEP) — 6.7; 7.1; 4.1 microvolts (uV) (amplitude)
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Phase 4 N=35 Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study
Glaucoma; Drugs · Normal Tension Glaucoma · Primary Open-angle Glaucoma
Primary: Changes in Vessel Density in Treatment Groups Assessed by OCT Angiography — -0.51; 2.59; -0.96; 0.96 percent change
N/A N=104 Is the RAPDx Pupillograph Able to Distinguish Between Glaucoma Subjects and Healthy Subjects?
Glaucoma
Primary: Amplitude Asymmetry of Pupil Constriction — 0.8; 0.29; 0.5; 0.16 millimeters
N/A N=16 Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma
Primary Open Angle Glaucoma
Primary: Blood Oxygenation — 60; 60; 60 percentage of oxygenation
N/A N=46 The Water Drinking Test in Glaucoma Study
Glaucoma
Primary: Maximum Intraocular Pressure Difference (Between mDCT and WDT) — -0.82 mmHg
N/A N=1,553 A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Study Eye — 22.18; 16.11 mmHg
N/A N=906 Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
Glaucoma · Glaucoma Suspect · Diabetic Retinopathy
Primary: Fundus Camera Images Via Telemedicine — 355; 384; 167 Participants
N/A N=44 Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect
Multiple Sclerosis · Glaucoma
Primary: Number of Participants With Detected Relative Afferent Pupillary Defect (RAPD) — 44; 37 participants
Phase 2 N=47 Safety and Efficacy of a Drug Delivery System in Glaucoma
Open-angle Glaucoma · Ocular Hypertension
Primary: Mean Change in Intraocular Pressure at Day 1 — -4.16; -4.57; -0.60 mmHg
N/A N=392 GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) — 22.0; -6.0; 22.0; -6.0 Millimeters of Mercury (mmHg)
Phase 3 N=1,636 Ocular Hypertension Treatment Study (OHTS)
Ocular Hypertension · Glaucoma
Primary: Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients — 9.5; 4.4; 20.0; 14.1 percent of participants
Phase 2 N=67 Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
Primary Open-Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Diurnal Intra Ocular Pressure (IOP) in Study Eye at Day 14: Stage I — 25.97; 26.25; 25.90; 26.44 mmHg — p=0.028
N/A N=7 Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
Glaucoma
Primary: Presence of Retinal Vascular Dysregulation (RVD) — 7; 4 Participants
N/A N=9 Home Tonometry With the I-care Tonometer for Glaucoma
Glaucoma
Primary: Intraocular Pressure — -1.85 mmHg
N/A N=4 Health Coaching for Glaucoma Patients
Glaucoma
Primary: Glaucoma Medication Adherence — 72 percentage of adherence time
N/A N=10 Study Comparing the P200TE and the P200TxE in Glaucoma Patients
Glaucoma
Primary: Qualitative B-Scan Assessment — 2.78; 2.77; 2.08 Mean score on a scale (0-3)
N/A N=56 Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — 2.32; -.30 cm/sec — p=.6261
Phase 4 N=86 Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Nocturnal IOP at Week 4 — 24.2; 23.6; 18.6; 18.9 mmHg
Phase 3 N=148 DE-111 Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
Open Angle Glaucoma or Ocular Hypertension
Primary: Change From Baseline in IOP (Intraocular Pressure) at End of Study — -1.8 mmHg
Phase 2 N=55 Safety and Efficacy of a Glaucoma Drug Delivery System
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Visual Acuity - Right Eye — 0.015; -0.044; -0.012 logMAR units
N/A N=358 An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure (IOP) in the Right Eye — -4.5 mmHg
Phase 2 N=323 Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma · Ocular Hypertension
Primary: Intraocular Pressure at Week 2 — 19.05; 18.92; 18.28; 17.86 mmHg
Phase 3 N=237 Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Glaucoma · Ocular Hypertension
Primary: Decrease From Baseline in Intraocular Pressure — 2.9; 1.6 mmHg
N/A N=622 Screening and Intervention for Glaucoma and Eye Health Through Telemedicine
Glaucoma
Primary: Physician Follow up — 150; 144; 97; 99 Participants — p=0.7399
Phase 2 N=10 A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Exfoliation Syndrome · Ocular Hypertension · Open Angle Glaucoma
Primary: Evaluate the Ocular Hypotensive Efficacy of Rho Kinase Inhibitor (AR-12286 0.5% and 0.7%) — 24.2; 25.8 mmHg